We came across a bullish thesis on GE HealthCare Technologies Inc. on Guardian Research’s Substack. In this article, we will summarize the bulls’ thesis on GEHC. GE HealthCare Technologies Inc.'s share was trading at $83.86 as of February 23rd. GEHC’s trailing and forward P/E were 15.74 and 16.69  respectively according to Yahoo Finance. Morgan Stanley Lifted GE HealthCare Target to $80 in Late October, Citing Strong Orders and Backlog Wichy/Shutterstock.com GE HealthCare Technologies Inc. engages in th ...

Key Takeaways SOLV posted Q4 adjusted EPS of $1.57 on $1.99B revenue, topping consensus estimates.SOLV saw organic growth across MedSurg, Dental, and HIS, led by infection prevention and restoratives.SOLV's gross margin fell 270 bps, while adjusted operating income declined 5.9% year over year.Solventum (SOLV) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.57, which beat the Zacks Consensus Estimate of $1.50 by 4.7%. The bottom line improved 11.3% year over year.GAAP EPS in the quarter ...

Industry Overview - The medical imaging industry is experiencing growth due to the increasing prevalence of chronic diseases, a rising geriatric population, and a focus on early and accurate diagnosis, with a projected CAGR of 6.65% through 2034 from $46.9 billion in 2026 [1] - Major companies in this sector, such as Hologic (HOLX) and GE HealthCare (GEHC), are attracting investor attention [1] Hologic (HOLX) Analysis - Hologic has developed multiple growth drivers through internal innovation and acquisitions, with Breast Health revenues increasing by 1.8% year over year in Q1 fiscal 2026, driven by Endomagnetics products [3] - GYN Surgical revenues rose by 8.7%, attributed to higher sales of MyoSure and Fluent devices, as well as the acquisition of Gynesonics [3] - However, Molecular Diagnostics revenues declined by 3.5% due to lower sales of COVID-19 tests and legacy assays, although growth in certain assays partially offset this decline [4] - Hologic ended Q1 with cash and cash equivalents of $2.17 billion and an adjusted net leverage ratio of 0.3X, and received FDA approval for its Aptima HPV Assay [5] - Hologic agreed to a buyout by Blackstone and TPG valued at up to $18.3 billion, offering shareholders $76 per share in cash, with a total potential value of $79 per share, indicating a 46% premium [6] GE HealthCare (GEHC) Analysis - GE HealthCare reported strong performance in Q4 2025, with double-digit organic revenue growth in Pharmaceutical Diagnostics and mid-single-digit growth in Imaging and Advanced Visualization Solutions, ending with a record backlog of $21.8 billion [7] - The company signed significant agreements, including a 7-year deal with the University of Rochester Medical Center, and plans to acquire Intelerad to enhance cloud-enabled imaging [8] - GEHC's D3 strategy focuses on using smart devices and digital tools for precision care, with new products contributing nearly 55% of revenues [10] - The company anticipates an increase in service agreement capture rates due to new innovations and has improved its business system, Heartbeat, leading to better sales and cash conversion [11] - Recent FDA clearances for new MR innovations and collaborations to advance AI in fetal ultrasound assessments further strengthen GEHC's position [12] Earnings Projections - The Zacks Consensus Estimate for Hologic's fiscal 2026 earnings indicates a 4.9% year-over-year growth to $4.47, with mixed estimate movements in the past 60 days [13] - For GE HealthCare, the earnings estimate for 2026 shows an 8.7% year-over-year growth to $4.99, with upward revisions in the last 60 days [14] Price Performance & Valuation - Hologic shares have increased by 0.7% over the past three months, while GE HealthCare shares have gained 4.2% [15] - Hologic trades at a forward price-to-sales (P/S) ratio of 3.87X, lower than its median, whereas GE HealthCare trades at a P/S of 1.76, in line with its median [16] Investment Outlook - Hologic's recent quarter performance was impacted by lower COVID testing and legacy STI test sales, with minimal upside potential from the buyout offer, suggesting current shareholders may consider exiting [19] - In contrast, GE HealthCare's strong segment performance and innovation strategy present it as a compelling investment opportunity, with bullish earnings projections [20]

Key Takeaways AVNS beat Q4 EPS and revenue estimates, but shares fell nearly 10% yesterday.Avanos Medical's SNS sales rose 8.7%, led by enteral feeding and neonate solutions growth.AVNS guides 2026 sales of $700-$720M and EPS of 90 cents to $1.10 amid tariff headwinds.Avanos Medical, Inc. (AVNS) reported fourth-quarter 2025 adjusted earnings per share (EPS) from continuing operations of 29 cents, down 32.6% year over year. However, the bottom line beat the Zacks Consensus Estimate of 24 cents by 20.8%.GAAP ...

Key Takeaways Inogen reported a narrower Q4 adjusted loss of 15 cents as revenues rose 2% year over year.International sales jumped 14.8%, offsetting a 5.1% drop in U.S. sales and a 4.5% fall in rentals.INGN guided 2026 revenues of $366M-$373M, about 6% growth at midpoint.Inogen, Inc. (INGN) incurred an adjusted loss per share of 15 cents for fourth-quarter 2025, which was narrower than the adjusted loss per share of 24 cents in the year-ago period and the Zacks Consensus Estimate of a loss of 36 cents per ...

Key Takeaways Stryker launched Synchfix EVT, a next-gen flexible fixation system for ankle syndesmotic injuries.SYK's device simplifies deployment, supports single-handed use and improves OR efficiency.Stryker's system is first approved for adolescents, expanding reach in ankle trauma care.Stryker (SYK) recently expanded its trauma portfolio with the launch of Synchfix EVT, a next-generation flexible syndesmotic fixation system to improve procedural efficiency and maintain effective ankle stabilization in p ...

Core Insights - Hims & Hers Health, Inc. reported a fourth-quarter 2025 EPS of 7 cents, down from 11 cents year-over-year, but exceeding the Zacks Consensus Estimate of 2 cents [1] - Full-year EPS was 51 cents, reflecting a 3.8% decrease from the previous year, yet surpassing the Zacks Consensus Estimate by 6.3% [1] Revenue Performance - Fourth-quarter revenues reached $617.8 million, a 28.4% increase year-over-year, but slightly below the Zacks Consensus Estimate by 0.2% [2] - Full-year revenues totaled $2.35 billion, marking a 58.9% improvement from the prior year and aligning with the Zacks Consensus Estimate [2] Geographical Results - U.S. revenues in Q4 2025 improved by 16.8% year-over-year to $554.1 million, while revenues from the Rest of the World surged to $63.7 million from $6.9 million in the previous year [3] Segment Analysis - Online Revenues for the quarter were $609.1 million, reflecting a 29.4% year-over-year increase, with total subscribers reaching 2.5 million, up 12.7% [4] - Wholesale Revenues were reported at $8.7 million, down 16.1% year-over-year [6] Margin and Expense Analysis - Gross profit increased by 20.3% year-over-year to $444.4 million, but gross margin contracted by 487 basis points to 71.9% [7] - Operating expenses rose 24% year-over-year to $435.2 million, leading to an operating profit of $9.2 million, a 50.6% decline from the previous year [8] Financial Position - Hims & Hers ended 2025 with cash and cash equivalents of $577.5 million, up from $300.3 million at the end of 2024 [9] - Cumulative net cash from operating activities was $300 million, compared to $251.1 million a year prior [9] Future Outlook - For Q1 2026, the company projects revenues between $600 million and $625 million, indicating a year-over-year growth of 2%-7% [10] - Full-year revenue guidance for 2026 is set between $2.7 billion and $2.9 billion, representing a growth of 15%-24% from 2025 levels [11] Strategic Developments - Hims & Hers has entered an agreement to acquire Eucalyptus, expanding its reach in consumer healthcare across multiple countries [13] - Recent product launches, including a cancer screening blood test and health assessment tools, are expected to enhance subscriber engagement and revenue [14] Market Reaction - Shares of Hims & Hers fell nearly 6.3% in pre-market trading following the earnings report [2] - The company currently holds a Zacks Rank of 4 (Sell) [16]

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 5, Patrick Wood from Morgan Stanley lifted the price target on GE HealthCare Technologies Inc. (NASDAQ:GEHC) from $80 to $85, maintaining an Equal Weight rating. GE HealthCare Technologies Inc. (GEHC) Positioned to Capitalize on Strong Demand Backlog The analyst noted the company’s fourth-quarter results, which beat expectations and improved the stock’s risk-reward ...

Core Insights - A study by the American Cancer Society indicates that only about 20% of eligible individuals in the U.S. underwent lung cancer screening in 2024, suggesting a significant opportunity to improve early detection and potentially prevent approximately 62,110 lung cancer deaths over five years [1] Company Developments - Tempus AI, Inc. has partnered with Median Technologies to integrate the eyonis LCS solution into the Tempus Pixel platform, enhancing lung cancer screening capabilities with AI-based software [2] - The company received FDA 510(k) clearance for its Tempus ECG-Low EF software, which identifies patients with low left ventricular ejection fraction [3] - Tempus strengthened its imaging capabilities through the acquisition of Arterys in 2022, integrating AI-driven imaging tools into its ecosystem [4] Peer Updates - GE HealthCare launched the Voluson Performance series and acquired icometrix to enhance its AI-powered brain imaging analysis capabilities [5] - NANO-X IMAGING LTD received CE mark certification for its Nanox.ARC system, which generates tomographic images from a single sweep [6] Stock Performance - Tempus' shares have declined by 14.3% over the past year, while the industry has seen a 33.6% decline, contrasting with a 17.7% increase in the S&P 500 [7] - The company currently trades at a forward 12-month Price-to-Sales (P/S) ratio of 6.45X, above the industry average of 5.66X [11] Earnings Estimates - Tempus AI's loss per share estimate for 2025 has remained unchanged over the past 30 days, with current estimates at -$0.59 for the current year and -$0.21 for the next year [12][13]

Core Insights - Integer Holdings Corporation (ITGR) reported adjusted earnings per share (EPS) of $1.76 for Q4 2025, a 23.1% increase year over year, exceeding the Zacks Consensus Estimate by 3.5% [1] - The company achieved revenues of $472.1 million in Q4 2025, reflecting a 5% year-over-year growth and surpassing the Zacks Consensus Estimate by 2% [2] - For the full year 2025, ITGR's revenues reached $1.85 billion, an 8% increase compared to 2024, with full-year EPS of $6.4, up 21% year over year [2] Revenue Breakdown - The Cardio and Vascular (C&V) segment generated revenues of $284.2 million in Q4 2025, an 11.3% increase year over year, driven by new product ramps and strong customer demand [5] - The Cardiac Rhythm Management & Neuromodulation (CRM&N) segment reported revenues of $167.3 million, down 1.9% year over year, due to a decline in Neuromodulation demand [6] - Revenues from the Other Markets segment totaled $20.5 million, down 13.2% year over year, attributed to the planned exit from the Portable Medical market [7] Margin and Expense Analysis - Gross profit for Q4 2025 was $124.8 million, a 6.8% increase year over year, with a gross margin of 26.4%, expanding by 50 basis points [8] - Selling, general and administrative expenses rose to $57.2 million, up 20.5% year over year, while total operating expenses increased by 15.2% to $68.8 million [10] - Adjusted operating profit was $83.3 million, reflecting a 9.6% increase from the prior year, with an adjusted operating margin of 17.6% [10] Financial Position - At the end of Q4 2025, ITGR had cash and cash equivalents of $17.2 million, down from $58.9 million at the end of Q3 2025, with total debt remaining flat at $1.19 billion [11] - Cumulative net cash flow from operating activities was $196.1 million, compared to $205.2 million a year ago [11] 2026 Guidance - For 2026, ITGR expects revenues between $1.826 billion and $1.876 billion, indicating a potential change of -1% to 1% from 2025 [12] - The company anticipates full-year adjusted EPS in the range of $6.29 to $6.78, reflecting a change of -2% to 6% from the previous year [12] Market Performance - Despite strong Q4 results, ITGR shares fell approximately 4% as investors focused on the 2026 guidance, which indicates slower adoption of new products [14] - Over the last six months, ITGR shares have declined by 22.7%, contrasting with a 4.9% decline in the industry and a 9.6% increase in the S&P 500 Index [15]